Jason Loveridge
Chief Executive Officer at 4SC AG
Profile
Jason Loveridge was the founder of Parvulus Suisse SA, founded in 2011, where he held the title of Chief Executive Officer from 2011 to 2014, and Invex Therapeutics Ltd., founded in 2019, where he held the title of Non-Executive Chairman from 2019 to 2023.
Currently, he is the Chief Executive Officer at 4SC AG since 2016, and a Director at Corticrine Ltd., Warambi Ltd., and Invex Therapeutics Ltd.
(United Kingdom).
He was also a Director & Investment Manager at Korda & Co. from 1991 to 1995, and a Principal at BioPharma Capital Ltd.
in 2003.
Additionally, he was a Non-Executive Director at Biofrontera AG, Actinogen Medical Ltd., and Parvulus Medical SAS, and a Gérant Sénior at IT Asset Management SA from 2005 to 2007.
He was also an Independent Non-Executive Director at Resonance Health Ltd.
from 2013 to 2017, and a Non-Executive Director at Actinogen Medical Ltd.
from 2017 to 2018.
Furthermore, he was a Director at Anaconda Pharma SASU, Executive Director & Owner at Warambi SARL from 2005 to 2020, and a Director at JDS BioPharma Pty Ltd.
from 2006 to 2020.
Dr. Loveridge received a doctorate degree from the University of Adelaide in 1988 and an undergraduate degree from The University of New South Wales in 1982.
Jason Loveridge active positions
| Companies | Position | Start |
|---|---|---|
| 4SC AG | Chief Executive Officer | 2016-09-20 |
| Warambi Ltd. | Corporate Officer/Principal | - |
Corticrine Ltd.
 Corticrine Ltd. Pharmaceuticals: MajorHealth Technology Part of Actinogen Medical Ltd., Corticrine Ltd. develops and manufactures drugs. The private company is based in Edinburgh, UK. Corticrine was acquired by Actinogen Medical Ltd. on December 01, 2014 for $4.97 million. | Director/Board Member | - |
| Invex Therapeutics Ltd. (United Kingdom) | Director/Board Member | - |
Former positions of Jason Loveridge
| Companies | Position | End |
|---|---|---|
| INVEX THERAPEUTICS LTD | Founder | 2023-07-09 |
| JDS BioPharma Pty Ltd. | Director/Board Member | 2019-12-31 |
| Warambi SARL | Director/Board Member | 2019-12-31 |
| ACTINOGEN MEDICAL LIMITED | Chairman | 2017-02-28 |
| RESONANCE HEALTH LIMITED | Director/Board Member | 2017-06-29 |
Training of Jason Loveridge
| University of Adelaide | Doctorate Degree |
| The University of New South Wales | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| 4SC AG | Health Technology |
| RESONANCE HEALTH LIMITED | Health Services |
| BIOFRONTERA AG | Health Technology |
| ACTINOGEN MEDICAL LIMITED | Health Technology |
| INVEX THERAPEUTICS LTD | Health Technology |
| Private companies | 13 |
|---|---|
Arthro Kinetics Ltd.
 Arthro Kinetics Ltd. Medical SpecialtiesHealth Technology Arthro Kinetics develops manufactures and markets advanced biological implants for joint regeneration and surgical instrument and access systems for endoscopic spine surgery. The Company aims to develop a portfolio of biological implants for insertion by endoscopic spine surgery techniques, thereby setting new standards of surgical care. The Company has developed and is marketing CaReS, its first biological cartilage repair product, and K.I.S.S., its comprehensive spinal surgical instruments system for endoscopic spinal access and surgical intervention. | Health Technology |
IT Asset Management SA
 IT Asset Management SA Investment ManagersFinance IT Asset Management SA (ITAM), established in 1994, is an independent asset management firm based in Paris, France. ITAM is wholly-owned by their management and employees. The firm provides financial advisory services and manages discretionary portfolios and mutual funds (FCPs and a compartment of a Luxembourg-based SICAV) for institutional clients and private individuals. | Finance |
| BioPharma Capital Ltd. | Finance |
| Korda & Co. | Finance |
Spark Therapeutics Ireland Ltd.
 Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Health Technology |
Anaconda Pharma SASU
 Anaconda Pharma SASU BiotechnologyHealth Technology Anaconda Pharma SAS provides biotechnology services. It offers biotechnology services and develops treatments against infections by human papillomavirus. The company was founded in 2003 and is headquartered in Villejuif, France. | Health Technology |
Parvulus Suisse SA
 Parvulus Suisse SA Medical SpecialtiesHealth Technology Parvulus Suisse SA provides medical technology. It focused on commercializing devices for cardiac surgery distribution, manufacturing, sales and distribution. The company was founded in March 20011 and is headquartered in Lonay, Switzerland. | Health Technology |
| Warambi SARL | |
| JDS BioPharma Pty Ltd. | |
| Parvulus Medical SAS | Distribution Services |
Corticrine Ltd.
Corticrine Ltd. Pharmaceuticals: MajorHealth Technology Part of Actinogen Medical Ltd., Corticrine Ltd. develops and manufactures drugs. The private company is based in Edinburgh, UK. Corticrine was acquired by Actinogen Medical Ltd. on December 01, 2014 for $4.97 million. | Health Technology |
| Warambi Ltd. | |
| Invex Therapeutics Ltd. (United Kingdom) |
- Stock Market
- Insiders
- Jason Loveridge
